Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
How Recent Developments Are Rewriting the Story for Sangamo Therapeutics [Yahoo! Finance]
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease [Yahoo! Finance]
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by analysts at
Wall St